The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan

J Gastroenterol. 2018 Oct;53(10):1168-1169. doi: 10.1007/s00535-018-1493-8. Epub 2018 Jul 6.

Authors

Shinya Maekawa¹, Nobuyuki Enomoto²

Affiliations

¹ First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi, 409-3898, Japan. maekawa@yamanashi.ac.jp.
² First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi, 409-3898, Japan.

PMID: 29980847
DOI: 10.1007/s00535-018-1493-8

No abstract available

Publication types

Editorial
Comment

MeSH terms

Benzimidazoles
Fluorenes
Genotype
Hepacivirus
Hepatitis C*
Humans
Japan
Red Cross
Sofosbuvir*

Substances

Benzimidazoles
Fluorenes
ledipasvir
Sofosbuvir